BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Original Article
[키워드] 1:1
95% CI
95% confidence interval
acute respiratory syndrome
age
BNT162b2 mRNA
BNT162b2 mRNA vaccine
Care
Clinical characteristics
conditions
Control
coronavirus
coronavirus disease
death
effective
Effectiveness
Estimated
evaluate
first dose
groups
Health
Hospitalization
Infection
Kaplan–Meier estimator
mass
outcome
outcomes
Population
randomized trial
Result
risk
SARS-CoV-2
second dose
setting
severe disease
study group
study outcome
subpopulation
symptomatic COVID-19
vaccination
Vaccine
were used
[DOI] 10.1056/NEJMoa2101765 PMC 바로가기 [Article Type] Original Article
[DOI] 10.1056/NEJMoa2101765 PMC 바로가기 [Article Type] Original Article